Topics

Latest "Karus Therapeutics Ltd" News Stories

23:00 EDT 28th March 2020 | BioPortfolio

Here are the most relevant search results for "Karus Therapeutics Ltd" found in our extensive news archives from over 250 global news sources.

More Information about Karus Therapeutics Ltd on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Karus Therapeutics Ltd for you to read. Along with our medical data and news we also list Karus Therapeutics Ltd Clinical Trials, which are updated daily. BioPortfolio also has a large database of Karus Therapeutics Ltd Companies for you to search.

Showing "Karus Therapeutics" News Articles 1–25 of 7,600+

Friday 27th March 2020

CAPSTONE THERAPEUTICS ANNOUNCES TRANSACTION WITH TOTALSTONE LLC

TEMPE, Ariz., March 27, 2020 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB: CAPS) (“the Company”) RECAPITALIZATION OF AND MERGER WITH TOTALSTONE LLC In March 2020, the Company entered into an agreement, which will be effective April 1, 2020, to obtain an interest in materials distribution company (TotalStone, LLC), which distributes masonry stone products for residential and comm...


Abeona Therapeutics Inc.: Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic

NEW YORK and CLEVELAND, March 27, 2020 (GLOBE NEWSWIRE) -- The COVID-19 pandemic has created extraordinary challenges across all aspects of healthcare. Many institutions and their brave staff of pr...

Protein Phosphatase 2A PP2A or EC 3.1.3.16 Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

Protein Phosphatase 2A PP2A or EC 3.1.3.16 Pipeline Review, H2 2019SummaryProtein Phosphatase 2A PP2A or EC 3.1.3.16 pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Protein Phosphatase 2A PP2A or EC 3.1.3.16 Pipeline Review, H2 2019, outlays comprehensive informatio...


Global Allergy Immunotherapies Market 2020-2024 | Evolving Opportunities with Aimmune Therapeutics Inc. and ALK-Abelló AS | Technavio

The global allergy immunotherapies market is poised to grow by USD 626.77 million during 2020-2024, progressing at a CAGR of about 7% during the forecast period. Request free sample pages This press release features multimedia. View the full release here:

Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2020-2024 | Evolving Opportunities with AllCells Corp. and bluebird bio Inc. | Technavio

The global hematopoietic stem cells transplantation (HSCT) market is poised to grow by USD 4.64 billion during 2020-2024, progressing at a CAGR of about 6% during the forecast period. Request free sample pages This press relea

Pear Therapeutics gets FDA nod for prescription digital therapeutic Somryst

Pear Therapeutics has secured approval from the US Food and Drug Administration (FDA) for its prescription digital therapeutic (PDT), Somryst, to treat adults with chronic insomnia. Somryst is The post Pear Therapeutics gets FDA nod for prescription digital therapeutic Somryst appeared first on NS Medical Devices.

CerSci Therapeutics to Present at the Upcoming 2020 Solebury Trout Virtual Global Healthcare Conference Series

DALLAS, TX / ACCESSWIRE / March 27, 2020 / CerSci Therapeutics ("CerSci"), a non-opioid pain relief drug development company based in Dallas, Texas today announced that Dr. Lucas Rodriguez, Chief Executive Officer plans to present an overview of the company and provide a business update at the upcoming Solebury Trout Virtual Global Healthcare Conference Series. During the 25 minute prese...

Takeda enters rare disease alliance with Evox Therapeutics

Takeda Pharmaceutical has entered a multi-target alliance with biotechnology company Evox Therapeutics to develop protein replacement and mRNA therapies for...Read More... The post Takeda enters rare disease alliance with Evox Therapeutics appeared first on Pharmaceutical Technology.

Novartis Close To EU Approval For Zolgensma At Last

Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending...   

Forge, Roche finalize potential deal for new antibiotic

Forge Therapeutics and Roche have partnered through a licensing agreement for Forge's FG-LpxC LUNG program, a new antibiotic  -More- 

FDA, Grifols to develop plasma therapeutics for COVID-19

The FDA and Grifols of Spain will collaborate with other agencies to collect plasma from patients that recovered from the nov -More- 

Sanofi Joins mRNA COVID-19 Club With Translate Tie-Up

The French drugmaker has joined the likes of Moderna, BioNTech and CureVac in advancing an mRNA vaccine against the virus...    

UK Biotechs Seek Government Help As Economic ‘Heart Attack’ Threatens Sector

Huge economic shock to sector could be quickly alleviated by early payment of R&D Tax Credits, says BIA.    

Cardiol Therapeutics Announces Filing of 2019 Year-End Financial Statements and MD&A

Cardiol Therapeutics Inc. filed its audited Year-end Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2019. The post Cardiol Therapeutics Announces Filing of 2019 Year-End Financial Statements and MD&A appeared first on Investing News Network.

Immune Regulation Ltd Appoints Jonathan Rigby as Chief Executive Officer

Pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases LONDON, UK, March 27, 2020 / B3C newswire / -- Immune Regulation Ltd, a clinical stage biotech company, today announces the appointment of Jonathan Rigby as CEO and a member of the Board of Directors. Based in the U.S., Jonathan is an experienced CEO ...

Xenetic Biosciences, Inc. Reports 2019 Year End Results and Provides Corporate Update

-Company continues to advance preclinical development of its XCART™ CAR T therapy platform - - Expands XCART resources by adding expertise in cell therapy translational science and CMC - - Cash on hand expected to fund operations through mid-2021 - FRAMINGHAM, MA / ACCESSWIRE / March 27, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a bioph...

Ehave, Inc. Appoints Dr. Mark Braunstein as Chief Psychedelic Officer

Dr. Braunstein is recognized worldwide in Psychedelic Psychiatry, which entails treating psychiatric disorders with psychedelics MIAMI, FL / ACCESSWIRE / March 27, 2020 / Ehave, Inc., (OTC PINK:EHVVF) (the "Company"), announced today that Dr. Mark Braunstein, DO, ABPN has been appointed to its Medical Advisory Board as its Chief Psychedelic Officer. Dr. Braunstein will join other member...

AstraZeneca Links with Silence Therapeutics

Anglo-Swedish drugmaker AstraZeneca has announced plans to collaborate with UK biotech Silence Therapeutics to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for treating cardiovascular, renal, metabolic and respiratory diseases.

Sanofi, Translate Bio To Develop Novel MRNA Vaccine Candidate Against COVID-19

PARIS (dpa-AFX) - Sanofi (SNY, SNYNF) announced Friday that its vaccines global business unit Sanofi Pasteur and Translate Bio (TBIO), a clinical-stage messenger RNA or mRNA therapeutics company, ...

U.S. Now Has Most Virus Cases, BSGM To Develop COVID-19 Drug, FDA Nod For BMY

Today's Daily Dose brings you news about BioSig Technologies' foray into COVID-19 drug development, FDA approval of Bristol-Myers' multiple sclerosis drug, delay in FDA panel review of Intercept Pharma's NASH drug candidate, and positive results of VBL Therapeutics' ovarian cancer trial.

Coronavirus Update: More Companies Join Therapeutics Accelerator, FDA Delays AdCom For First NASH Drug

As the global number of COVID-19 cases exceeds 500,000 for the first time, more biopharma companies throw their weight behind...   

Thursday 26th March 2020

Akcea Therapeutics Promotes Damien McDevitt to CEO

Akcea Therapeutics (NASDAQ: AKCA) has appointed Damien McDevitt as its chief executive officer, the company announced Tuesday. Akcea, a subsidiary of Carlsbad, CA-based Ionis Pharmaceuticals (NASDAQ: IONS), is advancing a group of experimental rare disease drugs discovered by its parent company. McDevitt had been serving as Akcea’s interim CEO since September 2019, when CEO Paula Soteropou...

Forge Inks Roche Deal For Antibiotic Aimed at Drug-Resistant Infections

Forge Therapeutics has set an agreement with Roche that gives the Swiss pharma giant the option to license a new antibiotic Forge is developing to treat serious drug-resistant bacterial lung infections. This week the preclinical-stage San Diego-based biotech announced that under the deal Forge will retain control of the program, FG-LpxC LUNG, until Roche decides […]

Epigenetic Therapeutics for Cardiovascular Disease

Cells, and hence organisms, have biological memory, recording prior exposures to facilitate future responses. By linking this recall to gene expression, coordinated transcriptional programs are triggered that define normal function and adaptive responses. Efficient, integrated gene expression is essential, as evident with inflammatory responses to infection or tissue repair after injury. Cellular ...

Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic

NEW YORK and CLEVELAND, March 27, 2020 (GLOBE NEWSWIRE) -- The COVID-19 pandemic has created extraordinary challenges across all aspects of healthcare. Many institutions and their brave staff of providers are now focused on caring for patients stricken by the virus.  We at Abeona are thankful for their sacrifices and efforts, and stand behind these healthcare institutions whose resources...


Quick Search

News Quicklinks